Wei Peng YONG
Wei Peng YONGSenior Consultant
[email protected]

Affiliations

Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore

Biography

Dr Yong Wei Peng is the associate director (research) and senior consultant from National University Cancer Institute, Singapore at the National University Hospital. Dr Yong obtained his medical degree and postgraduate training in University of Aberdeen, Scotland. After completing an oncology fellowship at the National University Hospital, he was awarded the A*star international clinical pharmacology fellowship at the University of Chicago. Upon his return to Singapore, he was awarded the Clinician Scientist Award to further his research into personalized therapy. In addition, Dr Yong leads the therapeutic arm of the Singapore Gastric Cancer Consortium and chairs the National Health Group Domain Specific Review Board.

Research Interest

His clinical and research interests are gastrointestinal cancer and drug development.

Selected Publications

  1. Low JL, Huang Y, Sooi K, Ang Y, Chan ZY, Spencer K, Jeyasekharan AD, Sundar R, Goh BC, Soo R, Yong WP. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. Int J Cancer. 2021 Jul 1;149(1):169-176. doi:10.1002/ijc.33534. Epub 2021 Mar 6. PMID: 33634869; PMCID: PMC9545741.
  2. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK.Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi:10.1200/JCO.20.03555. Epub 2021 Jul 22. PMID: 34292792; PMCID: PMC8445563.
  3. Chakrabarti J, Koh V, Steele N, Hawkins J, Ito Y, Merchant JL, Wang J, Helmrath MA, Ahmad SA, So JBY, Yong WP, Zavros Y. Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids. Cancers (Basel). 2021 Dec 7;13(24):6158. doi:10.3390/cancers13246158. PMID: 34944780; PMCID: PMC8699100.
  4. Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, Goh GH, Seet JE, Chee CE, Tan HL, Ho J, Ngoi NYL, Lee MXW, Muthu V, Chan GHJ, Pang ASL, Ang YLE, Choo JRE, Lim JSJ, Teh JL, Lwin A, Soon Y, Shabbir A, So JBY, Yong WP. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Ann Surg Oncol. 2022 Dec;29(13):8597-8605. doi: 10.1245/s10434-022-11998-z. Epub 2022 Sep 7. PMID: 36070113.
  5. Chia DKA, Sundar R, Kim G, Ang JJ, Shabbir A, So JBY, Yong WP. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Ann Surg Oncol. 2023 Mar;30(3):1889-1890. doi: 10.1245/s10434-022-12877-3. Epub 2022 Dec 23. PMID: 36564654.
  6. Choo J, Kua LF, Soe MY, Asuncion BR, Tan BKJ, Teo CB, Tay RYK, So J, Shabbir A, Guowei K, Tan HL, Chan G, Ma H, Ramachandran GK, Lum JHY, Chee CE, Sridharan S, Tan P, Sundar R, Yong WP. Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. Gastric Cancer. 2023 May;26(3):393-404. doi:10.1007/s10120-023-01364-7. Epub 2023 Feb 12. PMID: 36781556; PMCID:PMC10115710.
  7. Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P; Singapore Gastric Cancer Consortium. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut. 2023 Sep;72(9):1651-1663. doi: 10.1136/gutjnl-2022-328332. Epub 2023 Mar 14. PMID:36918265.
  8. Zhao JJ, Ong CJ, Srivastava S, Chia DKA, Ma H, Huang K, Sheng T, RamnarayananK, Ong X, Tay ST, Hagihara T, Tan ALK, Teo MCC, Tan QX, Ng G, Tan JW, Ng MCH, Gwee YX, Walsh R, Law JH, Shabbir A, Kim G, Tay Y, Her Z, Leoncini G, Teh BT, Hong JH, Tay RYK, Teo CB, Dings MPG, Bijlsma M, Lum JHY, Mathur S, Pietrantonio F, Blum SM, van Laarhoven H, Klempner SJ, Yong WP, So JBY, Chen Q, Tan P, Sundar R. Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases. Gastroenterology. 2024 Dec;167(7):1384-1398.e4.doi: 10.1053/j.gastro.2024.08.007. Epub 2024 Aug 13. PMID: 39147169.
  9. Shimura M, Matsuo J, Pang S, Jangphattananont N, Hussain A, Rahmat MB, Lee JW, Douchi D, Tong JJL, Myint K, Srivastava S, Teh M, Koh V, Yong WP, So JBY, Tan P, Yeoh KG, Unno M, Chuang LSH, Ito Y. IQGAP3 signalling mediates intratumoral functional heterogeneity to enhance malignant growth. Gut. 2025 Feb 6;74(3):364-386. doi: 10.1136/gutjnl-2023-330390. PMID: 39438124; PMCID:PMC11874294.
  10. Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31. PMID: 40454632.

* Corresponding author; # Co-first author